Medication Safety Guide

The 10 Rights of Medication Administration

Classic 5 + Expanded 10

Right Patient

2 identifiers confirmed

Right Drug

Generic & brand verified

Right Dose

Calculated & rechecked

Right Route

Matches prescription

Right Time

Within ±30 min window

Right Documentation

Record immediately after

Right Reason

Understand indication

Right Response

Monitor therapeutic effect

Right Education

Patient/family informed

Right of Refusal

Document & escalate

Patient Identification Protocol

Mandatory: 2 Independent Identifiers
Use at least two of the following — never use room/bed number alone:

Full name — ask patient to state name (do not lead)
Medical Record Number (MRN) — scan barcode or visual check
Date of birth — secondary identifier when MRN unavailable

Wristband Verification: Cross-match wristband data with Medication Administration Record (MAR) before every administration. For unconscious or confused patients, always use wristband + MRN; never rely on verbal confirmation alone.

Check wristband before each administration — not once per shift
Report missing or damaged wristbands immediately; replace before giving any medication
For look-alike patients (same name on ward), apply additional colour-coded alert wristband per hospital policy
BCMA scan counts as one identifier — still require a second

High-Alert Medications

HIGH-ALERT — Extra Verification Required Before Administration

Insulin — all types; verify dose independently; beware U-100 vs U-500 confusion
Heparin & LMWH — weight-based dosing; monitor aPTT/anti-Xa; flush vs therapeutic dose confusion
Warfarin — INR monitoring mandatory; multiple drug interactions
Concentrated Electrolytes — KCl concentrate, hypertonic NaCl (3%), MgSO4 ≥50% — MUST be diluted; NEVER give IV push
Chemotherapy agents — independent double-check; extravasation protocol
Opioids (morphine, fentanyl, hydromorphone, pethidine) — sedation scale monitoring, naloxone available
Neuromuscular blocking agents (vecuronium, rocuronium, suxamethonium) — NEVER store with other injectables; confirm intubation equipment at bedside
Anticoagulants (rivaroxaban, apixaban, dabigatran) — bleeding precautions, reversal agents checked
Hypertonic solutions — mannitol 20%, dextrose 50% — central line preferred
Thrombolytics (alteplase, streptokinase) — strict inclusion/exclusion criteria; bleeding risk

Storage Rule: High-alert medications must be stored in clearly labelled, segregated areas (red-lidded bins or locked high-alert cabinet). Concentrated KCl must NEVER be stored on general wards — remove from floor stock per JCI MM.01 standards.

LASA Drugs — Look-Alike / Sound-Alike

Tall-Man Lettering helps differentiate LASA pairs. The capitalised portion highlights the differing letters.

Drug A (Tall-Man)	Drug B (Tall-Man)	Risk / Distinction
CELEbrex (celecoxib)	CEREbyx (fosphenytoin)	COX-2 inhibitor vs anticonvulsant — life-threatening if confused
hydrOXYzine	hydrALAzine	Antihistamine/anxiolytic vs antihypertensive
metFORMIN	metoPROLOL	Biguanide antidiabetic vs beta-blocker
MORPHINE	HYDROmorphone	Hydromorphone is ~5× more potent; overdose risk if swapped
vinCRIStine	vinBLAStine	Both vinca alkaloids; different doses and toxicity profiles
DOPamine	DOBUTamine	Different receptor profiles; wrong selection in shock is critical
clonIDine	clonAZEpam	Antihypertensive vs benzodiazepine
glipIZIDE	glyBURIDE	Both sulfonylureas; dosing and duration differ

Independent Double-Check Protocol

When required: All high-alert medications (insulin, heparin, opioid infusions, concentrated electrolytes, chemotherapy, neuromuscular blockers), PCA pump setup, and blood product administration.

Who: Two registered nurses independently — never the same nurse checking their own work; pharmacist may serve as second checker for complex calculations
When: Before first dose, with each new bag/infusion change, and after any pump programming change
What to verify: Patient identity (2 IDs), drug name and concentration, prescribed dose, pump rate and VTBI, route, line attachment point, and expiry date
Both nurses must sign the MAR — document that an independent check was performed
Independent means: second nurse performs check without seeing first nurse's calculation; compare results only after both are complete

IV Administration Safety

Parameter	Gravity Infusion	Infusion Pump
Rate accuracy	±10–20% (position dependent)	±2–5% (use for high-alert drugs)
VTBI programming	Not applicable — use drip count	Always programme VTBI + rate
High-alert drugs	NOT recommended	Required
KVO rate after completion	Clamp line immediately	Set keep-vein-open ≤10 ml/hr

VTBI Calculation: Volume (ml) = Rate (ml/hr) × Time (hr). Always double-check with a second nurse for high-alert infusions. Programme pump with total volume, not just rate.

Flush Volumes: Peripheral line — 10 ml NS before and after each IV medication. Central line — 10–20 ml NS (per lumen). PICC line — 20 ml NS. Document flush volume in fluid balance chart.

IV Incompatibilities Quick Reference

Drug Pair	Compatibility	Clinical Note
Furosemide + Aminoglycosides (gentamicin)	Y-site OK (brief)	Both ototoxic — monitor hearing with prolonged co-administration; separate lines preferred
Phenytoin IV	NS only	Precipitates in glucose solutions. Max rate 50 mg/min; ECG monitoring required
Ceftriaxone + Calcium (IV)	NEVER in neonates	Fatal precipitate in lungs/kidneys reported in neonates. In adults: separate lines, flush between
TPN + IV Lipids	Separate line	Dedicated lumen for TPN; lipids can destabilise 3-in-1 admixtures if mixed improperly
Propofol	Strict asepsis	Discard unused vial within 12 hours of opening. Single-patient use only. Lipid emulsion supports microbial growth
Diazepam + most IV solutions	Incompatible	Adsorbs to PVC tubing; precipitates in aqueous solutions — use undiluted or polyethylene tubing
Amphotericin B + NS	Incompatible	Use D5W only for reconstitution and infusion
Vancomycin + Piperacillin-Tazobactam	Flush between	Risk of AKI when co-administered; separate lumen if possible; monitor renal function daily

Intramuscular Injection

Site	Max Volume	Needle Size	Key Points
Ventrogluteal (VG) — preferred	3–5 ml	21–23G, 38 mm	Safest site; away from major vessels/nerves; used for adults and children >7 months
Deltoid	1–2 ml	23–25G, 25 mm	Vaccines, small volumes; avoid if muscle atrophied; palpate for radial nerve
Vastus Lateralis	1–3 ml (infant: 1 ml)	22–25G, 16–38 mm	Preferred for infants and toddlers; anterolateral thigh

Z-Track Technique: Displace skin 2.5–3.5 cm laterally, inject at 90°, hold 10 seconds, release skin before withdrawing. Prevents tracking of irritant drugs (e.g., iron dextran, hydroxyzine) into subcutaneous tissue.

Aspirate not routinely required for standard IM sites per WHO/CDC 2020 guidance (VG, deltoid, vastus lateralis)
Rotate sites when repeated injections are needed — document site used
Do not massage after injection (may increase absorption rate unpredictably and cause bruising)

Subcutaneous Administration — Insulin Focus

Site	Absorption Rate	Notes
Abdomen (2 inches from navel)	Fastest	Preferred for rapid-acting insulin
Outer upper arm	Moderate	Use for intermediate-acting
Anterior thigh	Slowest	Good for long-acting (basal) insulin
Upper outer buttock	Slow-moderate	Least used; avoid if patient ambulatory

Rotation Protocol: Rotate within same region (not between regions) to maintain consistent absorption. Move each injection site at least 1 cm from previous. Document site on rotation chart. Inspect for lipohypertrophy — avoid injecting into lumpy tissue.

Technique: 45° angle for thin patients or short needles; 90° for most adults. Pinch skin fold. Do not aspirate. Hold pen/syringe in place for 10 seconds after injection before withdrawing.

Enteral Tube Medications — Crush Safety

Category	Examples	Can Crush?	Reason
Immediate-release tablets	Paracetamol, metronidazole, furosemide	Yes	No special coating; crush and dissolve in 15–30 ml water
Modified / extended-release	Metoprolol XL, diltiazem CD, morphine SR	Never	Dose-dumping risk — full dose released rapidly, potentially fatal
Enteric-coated	Aspirin EC, omeprazole (some), bisacodyl EC	Never	Coating protects stomach or prevents gastric degradation
Sublingual / buccal	Glyceryl trinitrate, buprenorphine	Never via tube	Designed for mucosal absorption; enteral route inactivates
Capsule contents (some)	Omeprazole granules, fluoxetine liquid	Specific guidance needed	Some granules can be opened into water; check per drug

Tube Flush: Flush with 30 ml water before and after each medication; between each drug if giving multiple. Use liquid formulations first where available. Never mix medications together in the syringe.

PCA — Patient-Controlled Analgesia Safety

Parameter	Typical Setting	Safety Principle
Demand dose (bolus)	Morphine 1 mg / Fentanyl 20 mcg	Set per pain team order; never exceed recommended bolus
Lockout interval	5–10 minutes	Prevents stacking; pump locks out further doses during interval
1-hour limit	Morphine ≤ 10 mg/hr	Hard limit on pump — prevents cumulative overdose
Background infusion	Usually 0 in opioid-naive patients	Basal infusion increases overdose risk; use only in opioid-tolerant

PCA Monitoring Requirements

Sedation score (RASS or Pasero Opioid Sedation Scale) every 2 hours for 24 hours, then every 4 hours
Respiratory rate, SpO2 monitoring — pulse oximetry continuous for first 24 hours post-initiation
Pain score (NRS 0–10) at same intervals; document pump readings (total doses delivered, number of attempts)
Naloxone 400 mcg/ml at bedside; call anaesthesia/pain team if RR <10, RASS ≤ −3, or SpO2 <93%
Only patient presses the button — educate family not to press on patient's behalf ("PCA by proxy")

Allergy Documentation Standards

Required fields when documenting a drug allergy: Drug name (generic preferred), reaction type (urticaria, angioedema, bronchospasm, etc.), severity (mild/moderate/severe/life-threatening), date of reaction, source of information (patient report, medical record, family). Update allergy list in EMR at every encounter.

Type	Definition	Examples	Action
True Allergy	Immune-mediated response (IgE or non-IgE)	Penicillin anaphylaxis, Stevens-Johnson syndrome	Document as ALLERGY; avoid drug class; alert physician
Allergic Reaction	Immunological but not anaphylactic	Rash, urticaria, pruritus	Document type and severity; cross-reactivity risk assessment
Intolerance	Non-immune, pharmacological side effect	Codeine → nausea/vomiting, ACEi → cough	Document as INTOLERANCE (not allergy); may be manageable
Pseudo-allergy	Mast cell degranulation without IgE	Morphine → histamine flush, vancomycin → red-man syndrome	Rate-related; document; slower infusion may prevent recurrence

Anaphylaxis Management Algorithm

Anaphylaxis — Act Within 60 Seconds

Diagnosis triggers: acute onset of ≥2 body systems (skin, respiratory, CVS, GI) after exposure to likely allergen, OR cardiovascular compromise alone after known allergen

Adrenaline (Epinephrine) 0.5 mg IM (1:1000 solution) — STAT
Inject into outer mid-thigh (through clothing if necessary). This is the first-line treatment — do not delay for antihistamines or steroids.
Call for help immediately
Activate emergency response. Lay patient flat with legs elevated (unless breathing difficulty — then semi-recumbent). Do NOT allow patient to stand — fatal hypotension can occur.
Oxygen 15 L/min via Non-Rebreather Mask
Establish IV access ×2 large-bore cannulae (16–18G) simultaneously.
IV Fluid Resuscitation
500–1000 ml crystalloid (0.9% NaCl) bolus rapidly. Titrate to blood pressure. Repeat as needed up to 2–3 L.
Secondary medications (after adrenaline)
Chlorphenamine 10 mg IV slow push. Hydrocortisone 200 mg IV. These treat prolonged/biphasic reactions — they are NOT a substitute for adrenaline.
Reassess at 5 minutes — repeat adrenaline if not improving
Second dose 0.5 mg IM (1:1000) if inadequate response. Third dose may be given at 5-minute intervals. Consider IV adrenaline infusion in refractory anaphylaxis (ICU setting only).
Continuous monitoring
HR, BP, SpO2, respiratory rate, urine output every 5 minutes until stabilised. Admit to HDU/ICU. Warn of biphasic reaction risk (can recur 1–72 hours later). Observe minimum 6–24 hours post-event.

Post-event: Complete incident report. Refer patient to allergist. Issue MedicAlert information. Document adrenaline auto-injector prescription if applicable.

Cross-Reactivity Warnings

Primary Allergy	Cross-Reactant	Risk Level	Guidance
Penicillin	Cephalosporins	1–2% (similar side chain)	Low risk if mild penicillin allergy; avoid if history of penicillin anaphylaxis; consider allergy testing
Penicillin	Carbapenems	<1%	Very low cross-reactivity; may use with caution and monitoring
Sulfonamide antibiotics	Thiazide diuretics, furosemide, sulfonylureas	Low but documented	Non-antibiotic sulfonamides have different allergenic structure; assess individually
NSAID / Aspirin	Other NSAIDs (cross-intolerance)	Moderate	Cross-intolerance (not true cross-allergy) in aspirin-exacerbated respiratory disease (AERD)
Latex	Kiwi, avocado, banana, chestnut	30–50% latex-fruit syndrome	Document latex allergy; use latex-free equipment; advise dietary caution
Iodinated contrast	Povidone-iodine, seafood	Overstated — different allergy mechanisms	Seafood/iodine allergy does NOT predict contrast reaction; assess independently

GCC-Specific Pharmacogenomic Considerations

Aspirin / NSAID Sensitivity: Aspirin-exacerbated respiratory disease (AERD/Samter's triad — asthma + nasal polyps + aspirin sensitivity) has higher prevalence in Arab/Middle Eastern populations. Always screen for asthma and nasal polyps before prescribing aspirin or NSAIDs.

Codeine Poor Metabolisers: CYP2D6 poor metaboliser phenotype affects ~1–3% of Middle Eastern patients (compared to less analgesic effect from codeine). Conversely, ultra-rapid metabolisers (higher frequency in some GCC populations — up to 5%) convert codeine to morphine very rapidly, causing opioid toxicity at standard doses. Consider tramadol or morphine as alternatives.

G6PD Deficiency: Relatively common in Gulf Arab populations (~5–15% males). Avoid oxidant drugs: primaquine, dapsone, high-dose aspirin, nitrofurantoin, certain sulfonamides — risk of haemolytic anaemia. Check G6PD status before prescribing.

ACE Inhibitor Cough: Higher incidence of dry cough in Arab/South Asian populations. Document as intolerance (not allergy). Substitute ARB (e.g., losartan) as clinically appropriate.

Medication Error Classification

Error Type	Definition	Examples
Prescribing error	Incorrect drug, dose, route, or indication written by prescriber	Wrong dose for renal impairment; missing allergy check; illegible handwriting
Transcription error	Inaccuracy in copying or entering prescription into MAR/EMR	Decimal error (1.0 mg read as 10 mg); wrong drug selected in dropdown
Dispensing error	Pharmacy dispenses wrong drug, dose, or concentration	Wrong concentration of heparin supplied; LASA drug mix-up in dispensing robot
Administration error	Nurse gives wrong drug, dose, route, time, or to wrong patient	IV drug given IM; missed dose not documented; wrong patient wristband not checked
Monitoring error	Failure to review therapeutic levels, labs, or patient response	No INR checked with warfarin; aminoglycoside levels not monitored; toxicity missed

Near-Miss: An error that was caught before reaching the patient. Must still be reported — near-misses reveal system vulnerabilities.
Adverse Drug Event (ADE): Harm caused by medication, whether due to error or not.
Adverse Drug Reaction (ADR): Unintended harmful response to a drug given at a normal dose — not an error per se, but must be documented and reported to pharmacovigilance.

Swiss Cheese Model of Error

Each layer represents a safety barrier. When holes (failures) align across all layers, harm reaches the patient.

Error
Source

→

Prescribing

Dispensing

Administration

Monitoring

→

Patient
Harm

Key insight: No single failure causes harm. Multiple simultaneous system failures are required. Therefore, reinforce every layer — do not rely on one defence. Report near-misses to patch holes before they align.

Top 5 Error Prevention Strategies

Never accept verbal/telephone orders without read-back.
Receive verbal order → write it down in full → read back slowly to prescriber → obtain confirmation and counter-signature within 24 hours. Verbal orders only in emergency situations.
Standardised concentration infusions.
Adopt hospital-wide standard concentrations (e.g., morphine always 1 mg/ml, dopamine always 1.6 mg/ml in 250 ml NS). Eliminates calculation variation between nurses. Publish and laminate the formulary at each nursing station.
Smart pump libraries with Dose Error Reduction Software (DERS).
Programme drug library with hard and soft limits. Hard limits reject dose outright; soft limits require override with documented reason. Analyse override data monthly to refine library limits.
Mandatory pharmacist review before high-alert drug administration.
Clinical pharmacist verification for all new high-alert infusions. Pharmacist attends ICU ward rounds. Reconciliation review on admission, transfer, and discharge.
Strict sterile / non-sterile preparation separation.
IV admixtures prepared in laminar-flow pharmacy clean room where possible. Ward-prepared IV drugs: designated clean preparation area, aseptic non-touch technique (ANTT). Separate storage of IV and oral formulations of the same drug.

Barcode Medication Administration (BCMA)

How BCMA works: Nurse scans own ID badge → scans patient wristband barcode → scans medication barcode. System verifies 5 Rights electronically. Alert generated for wrong patient, drug, dose, route, or time outside window. Documents administration in real time in MAR.

Do not work around BCMA by pre-scanning medications before reaching the patient
If barcode is damaged, follow hospital manual override protocol with dual-nurse verification
BCMA adoption in GCC is increasing — DHA Dubai, SEHA Abu Dhabi, MOH KSA institutions progressively deploying systems (2022–2025 strategic plans)
BCMA reduces wrong-patient and wrong-drug errors by 50–80% in published studies
Override data (bypasses) must be audited weekly by charge nurse and pharmacy

Incident Reporting — GCC / JCI Requirements

Event Type	Reporting Timeline	Mandatory Reporter
Serious adverse drug event / sentinel event	Immediate verbal → 24-hour written report	Any clinician; hospital quality department notifies MOH
Medication error reaching patient (any harm)	Within 24 hours	Nurse who discovers or administers; charge nurse
Near-miss / no harm event	Within 48–72 hours	Any staff member via non-punitive reporting system
Adverse drug reaction (unexpected)	Within 15 days (serious: 7 days)	Prescriber + nurse → hospital pharmacovigilance unit → national authority

Anonymity & Non-Punitive Culture: JCI and GCC MOH policies protect good-faith reporters. Incident reporting systems (e.g., RL Solutions, Quantros) allow anonymous submission. The purpose is system improvement, not individual blame. Nurses are protected when reporting in good faith.

Controlled Drug Waste & Narcotic Register

Two-Nurse Witness Requirement: Any unused portion of a controlled substance (opioid, benzodiazepine, barbiturate) must be witnessed by a second registered nurse before disposal. Both nurses sign the narcotic register with date, time, amount wasted, and disposal method (e.g., drug destruction bin, sink dilution per policy).

Narcotic register: paper or electronic; each entry includes drug name, strength, batch number, amount drawn, amount given, amount wasted, two signatures
Count controlled drugs at every handover (shift-to-shift narcotic count); discrepancy reported immediately to pharmacist and nurse manager
Partial ampoule waste: draw full ampoule, give prescribed amount, witness and document waste of remainder immediately at bedside — never return to ampoule or store partial
UAE Federal Law No. 14/1995: narcotics register must be retained for minimum 5 years; subject to MOH inspection
Saudi Arabia SFDA regulations: similar requirements; controlled substance licences required for units that store stock